Adenocyte

About

Funding history · 3 rounds · $10.0M total

Q&A

What is Adenocyte's primary focus?

Adenocyte is a medical technology company focused on the early detection of adenocarcinoma and its precancerous precursors using patented ultrasound technology.

When was Adenocyte founded?

Adenocyte was founded in 2020.

Where is Adenocyte headquartered?

Adenocyte is headquartered in Jerusalem, Israel, with laboratories in Haifa and Jerusalem.

Which funding rounds has Adenocyte completed?

Adenocyte has completed two grant rounds in 2023 and 2024, and a Seed round in May 2026.

How much capital has Adenocyte raised in total?

Adenocyte has raised a total of $10,000,000 USD.

Which investors participated in Adenocyte's Seed round?

iGan Partners led Adenocyte's Seed round in May 2026.

What is Adenocyte's core technology?

Adenocyte's core technology is the LINFU® (Low Intensity Non-Focused Ultrasound) platform, which uses microbubble-enhanced low-intensity non-focused ultrasound to release epithelial cells for cytological analysis.

What is the purpose of the LINFU® system?

The LINFU® system is designed to detect glandular dysplasia and very early carcinoma in the pancreas, breast, and prostate, and has entered clinical use for screening high-risk patients.

Who is the founder and CEO of Adenocyte?

Dr. Mark Rutenberg is the Founder and CEO of Adenocyte, appointed in December 2020.

How many employees did Adenocyte have in August 2026?

Adenocyte had 15 employees in August 2026.

Team · 10

Dr. Mark Rutenberg

Founder · Founder and CEO

Robert Harow

Chief Financial Officer

F. Scott Corbett

Chief Medical Officer

Drore Eisen

Medical Research Director

Dan Adam

Chief Technology Officer

Aaron Rutenberg

Director of Technical Operations

Dor Meron

Biomedical Engineer

Eric Hirsch

Director of Brand Experience and Sales Enablement

Yoni Mozeson

Marketing Director

Emmanuel Loeb

Veterinary Pathologist, Preclinical Studies

Sectors & technology